e-learning
resources
Glasgow 2004
Monday 06.09.2004
Management of lung cancer and innovative therapies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer
Y. C. Kim, K. S. Kim, Y. I. Kim, S. C. Lim, C. M. Park, K. J. Na, S. J. Ahn, K. O. Park (Kwangju, South Korea)
Source:
Annual Congress 2004 - Management of lung cancer and innovative therapies
Session:
Management of lung cancer and innovative therapies
Session type:
Oral Presentation
Number:
1523
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. C. Kim, K. S. Kim, Y. I. Kim, S. C. Lim, C. M. Park, K. J. Na, S. J. Ahn, K. O. Park (Kwangju, South Korea). Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer. Eur Respir J 2004; 24: Suppl. 48, 1523
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Targeted therapy in non-small cell lung cancer
Source: Breathe 2012; 8: 206-215
Year: 2012
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond
Source: International Congress 2017 – State of the art session: "Lung cancer"
Year: 2017
Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
Smoking habits and erlotinib response in non-small-cell lung cancer (NSCLC) treatment
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept